VHL is due to report this week.
I'm hoping chairman, Dr Wayne Millen, will comment on:
1. Transgene/Novartis progress in commercializing lung cancer platform TG-4010;
2. Prospects of VHL consummating a $3m placement to clients of Patersons Securities when the VHL share price is currently 20pc below the notional placement price;
3. In the event of the placement being aborted, likelihood of the Paul Hopper/Pathway Oncology drug deal being consummated;
4. When the Co-X-GENE Scientific Board will formed and who'll be on it.
Add to My Watchlist
What is My Watchlist?
